Pushing a Covid Vaccine for Profit
Gilead’s COVID-19 drug remdesivir is being supported as a potential coronavirus treatment. Obviously, anyone who buys shares stands to earn a lot of money if the drug gets approved, more so if vaccinations/treatment with remdesivir (not a traditional vaccine as we know it) are made mandatory. With mandatory vaccination, Gilead could theoretically sell 330 million doses, one to each American. The firm could sell 660 million or 990 million doses in the US alone.
Bill Gates, who has donated $250 million toward development of a vaccine, is suggesting that we may need to take multiple doses. Not content with just the US distribution, Gates is aiming at distributing this drug to 70%-80% of the global population. To this end, he is calling for 7 billion doses to be manufactured and sold. And while many of these treatments will probably be free to the recipients, they will be paid for by donors or governments. And massive profits will be earned.
As a result of the incredibly large sum of money at stake, Congress took it very seriously when proprietary information about remdesivir was leaked. A small, core group of insiders in possession of non-public information could use that information to time the selection, purchase and sale of their stocks, unfairly amplifying their profits. For this reason, Congress has launched an investigation into insider trading.
Gilead has been the subject of a previous insider trading scandal. A Florida man was charged with insider trading on a major Gilead deal after an ex-Morgan Stanley broker gave him a tip that allowed him to buy shares at an 89% premium. He sold the shares, earning $250,000 in profits. The judge made him hand over all the money to the authorities and spend a year in prison.
Telltale Signs of Insider Trading
Insider trading may already have occurred. Gilead’s shares increased in value by 10% after the media released positive news regarding trial data. But, this is to be expected as each positive trial or news report ostensibly moves the drug closer to approval and release. The suspicious activity, however, came when options on the drug were suddenly trading in unusually high volumes, hours before the report, doubling overnight. When the company’s shares were trading at $75, four large blocks of options were purchased for about $1.5 million each. The option purchasers expected the price to reach $87.50 by mid-August. Such unusual activity attracted the attention of the SEC and regulators have since opened an investigation.
Gilead spent $2.45 million on lobbying in the first quarter of the year. Coincidentally, the first quarter was also when Congress passed the Coronavirus Aid, Relief, and Economic Security Act, which included funding for the development of coronavirus vaccines. Immediately afterwards, in May, the Food and Drug Administration (FDA) authorized the emergency use of remdesivir for coronavirus patients. Gilead reported that they expected the US government to coordinate distribution of the drug to hospitals across the country.
Gilead paid nearly $590,000 in 2019 to join the trade group Pharmaceutical Research and Manufacturers of America (PhRMA), one of the most influential trade groups on Capitol Hill with 183 lobbyists. Ben Wakana, executive director of Patients for Affordable Drugs, an advocacy group, said that he “suspects Gilead is laying the groundwork to push back against congressional attempts to control the prices of COVID-19 drugs.” The fear is that, if Gilead pumps enough money into lobbying, it might be able to convince Congress to allow them to charge an exorbitant amount for the drug. Gilead’s hepatitis C pill, launched in 2013, for example, cost $1,000 a pill.
In July, Business Insider reported that the US had purchased 90% of the world’s supply of remdesivir. At this point, the price of the drug was $2,340 a course for developed nations. Gilead Sciences “agreed to sell more than 500,000 treatment courses to the US until September.” A cheaper, generic version of the drug exists, but because of the patent owned by Gilead, the generic cannot be sold in developed countries. This means that only the most expensive version of the drug can be sold in the US. Meanwhile, Gilead has authorized companies in 127 developing countries to manufacture and sell the cheaper version.
Remdesivir vs HCQ
Almost immediately after the FDA approved the use of remdesivir, a Chinese study was released, demonstrating that remdesivir was no more successful in treating covid than a placebo. And yet, remdesivir remains the drug being touted by mainstream media. Meanwhile other, extremely cheap treatments have been widely used but are being downplayed or outright vilified by Dr. Fauci and the mainstream media.
St. Lukes Clinic reported that Hydroxychloroquine (HCQ) and zinc have been successfully and widely used in Europe and parts of Asia. “International testing of hydroxychloroquine treatment of coronavirus shows countries that had early use of the drug had a 79% lower mortality rate.” An open letter to Dr. Fauci from physicians supporting HCQ stated “As experience accrued in treating COVID-19 infections, physicians worldwide discovered that high-risk patients can be treated successfully as an outpatient, within the first 5 to 7 days of the onset of symptoms, with a “cocktail” consisting of hydroxychloroquine, zinc, and azithromycin (or doxycycline).”
What Did Fauci Know and When Did He Know It?
Questions have arisen as to what Dr. Fauci knew and when, regarding coronavirus and if he in some way has colluded with China and the WHO to misrepresent the pandemic. Judicial Watch has filed a lawsuit seeking access to the records of Dr. Fauci’s communication with WHO, to find out what they knew, what they said, and what the China connection was. Dr. Fauci and many in government are pushing for mandatory masking, lockdowns, and school closure in spite of increasing counter arguments from legitimate medical authorities who say these measures are unnecessary or even damaging.
The same individuals supporting mandatory masking, lockdowns, and school closure are calling for an immunity passport. “Governments are still exploring whether certificates, wristbands or mobile apps could get those who have recovered from Covid-19 working and traveling again.” Opponents of these policies are concerned about the loss of freedoms and anonymity that they would cause. Along with these draconian control measures, members of government are discussing making covid vaccination mandatory, which would further drive up the profits of drug companies.
Joe Biden supports a mandatory mask law saying, “Every governor should mandate mandatory mask wearing.” By convincing the public of the need for masks and lockdowns, they will reduce resistance to mandatory vaccinations, which will result in a nice profit for those who have purchased shares in the drug manufacturers. In April, Dr. Scott Atlas, the replacement for Dr. Fauci, Trump’s new pandemic response leader, has spoken out against mandatory masking and lockdowns and in favor of opening schools.
In April, 2020, Dr. Atlas suggested the fatality and ICU rates had reached a point that the pandemic was over stating, “The data is in. It is time to stop the panic and end the total isolation.” He also stated that 99.5% of people were at zero risk of dying from Covid. If mainstream media were widely reporting Dr. Atlas’ claims that the pandemic were over and that covid mortality rate is only .5%, this would be bad for the Biden camp, who want stricter lockdowns, masking, and school closures. It would be even worse for those holding shares in remdesivir.
New Right Network depends on your support. Donate now